Global hiring within the ZRG Life Sciences Index was up 11.1% from the first quarter, finishing at 87.8, the second highest level over the last 9 quarters. Demand for new employees in Europe drove the index up globally as EMA reported a 34% increase in hiring levels overall. Medical device and diagnostics accounted for much of the growth, with over 1,300 new jobs sited in our index companies alone.
What’s Hot
- Europe is hiring! The EMA numbers are showing a new all-time high mark for total demand;
- Medical Device and Diagnostics is rebounding with a 22.8% increase in job opportunities around the world;
- Hiring for sales talent has returned with a 40% increase in sales talent opportunities within the index companies;
- Manufacturing roles jumped 100% in the quarter reflecting the trend of geographic shifts in where product is made around the world.
What’s Not
- Demand in Asia Pacific dropped by 11% in the quarter, perhaps reflecting a slowing growth rate;
- Quality, Regulatory and Clinical jobs dropped 16% from last quarter, although the total number of roles still remains robust;
- Research and Development Roles dipped 11%.
- Private Equity Investment in the sector is still off 50% from last year’s levels.
While EMA was the regional story, with a broad increase in hiring across medical device and pharma, one juggernaut is leading the charge. Novartis had a large increase in “job share” in this quarter’s index, with increased activities across all functions and regions in EMA. Driving hiring in the medical device and diagnostics in EMA was the big three led by Siemens, Philips and GE Medical. The America’s showed growth of 8% in new and open jobs in the quarter while APAC retreated 11.5%.
For a full copy of the report, go to www.zrgpartners.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.